martinhoenigl.bsky.social
Martin Hoenigl
@martinhoenigl.bsky.social
1.1K followers 180 following 18 posts
Tenure Track Prof for Translational Mycology, Medical University Graz, Austria; Past President ECMM.❤️for Clinical Mycology, ⬛⬜1909 ⚽️ Rams 🏈#StandwithUkraine
Posts Media Videos Starter Packs
Pinned
martinhoenigl.bsky.social
Martin Hoenigl @martinhoenigl.bsky.social · Nov 14
👉Participate in ECMM Candida IV

🌎wide study on candidemia caused by non-albicans Candida spp.

Requirement: clinical data & isolate (isolate not req for C.auris cases)

Reward: Reimbursement & Authorship

Observation period: 04/2024 - 09/2025

Interested? 📧 [email protected] or DM
6 15
Reposted by Martin Hoenigl
sarah-delliere.bsky.social
Sarah Dellière @sarah-delliere.bsky.social · Sep 4
✨📄 What about the untapped therapeutic potential of the immune response in invasive aspergillosis ? Here’s some rational, pre-clinical and clinical evidence. Huge thanks to our amazing 🌍 team!
🔗 bit.ly/46kajHr
@simonfeys.bsky.social @agocarvalho.bsky.social @martinhoenigl.bsky.social
9 15
martinhoenigl.bsky.social
Martin Hoenigl @martinhoenigl.bsky.social · Jun 18
🔥🗞️Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study.

Groundbreaking work on a very promising new antifungal. Free access here:

authors.elsevier.com/c/1lHca5E-Uo...
authors.elsevier.com
1 3
Reposted by Martin Hoenigl
normanvanrhijn.bsky.social
Norman van Rhijn @normanvanrhijn.bsky.social · Jun 12
🚨Our latest review in Thorax about the impact of climate change focusing on fungal pathogens in Europe 🌍

A truly enjoyable collaboration with Sarah Sedik @germhuntermd.bsky.social @martinhoenigl.bsky.social and @mbottery.bsky.social

thorax.bmj.com/content/earl...
14 27
Reposted by Martin Hoenigl
germhuntermd.bsky.social
Ilan Schwartz @germhuntermd.bsky.social · Jun 8
Addressing Antifungal Drug Resistance — A “One Health–One World” Challenge

@grthompsonmd.bsky.social and Angel Desai

www.nejm.org/doi/full/10....
Addressing Antifungal Drug Resistance — A “One Health–One World” Challenge | NEJM
Use of some antifungal pesticides may select for resistant fungi in the environment, which can then endanger human health. Coordinated regulatory processes in this area are important.
www.nejm.org
8 22
Reposted by Martin Hoenigl
germhuntermd.bsky.social
Ilan Schwartz @germhuntermd.bsky.social · Jun 9
Climate change: shifting boundaries of fungal disease in Europe and beyond

New review in Thorax

by @mbottery.bsky.social Sarah Sedik @germhuntermd.bsky.social @martinhoenigl.bsky.social @normanvanrhijn.bsky.social

thorax.bmj.com/content/thor... #MedSky #IDSky #PulmSky #ClimateSky #MedMycoSky
Health risks with environmental changes and mould exposure. Key impacts of flooding include increased precipitation, rising sea levels and land use changes, leading to indoor mould growth and health risks such as respiratory issues, asthma exacerbation and mould infections. Case studies highlight varying health outcomes from Hurricane Katrina and Rita (2005), Colorado Flood (2013) and Hurricane Harvey (2017). Drivers of emerging fungal pathogens in a changing world. Climate change factors, such as rising temperatures and increasing resistance to fungicides, enhance fungal thermotolerance and drive the emergence of pathogens. Social determinants, including urbanisation, global travel and limited healthcare access, heighten human vulnerability to fungal infections. Other contributing factors, like environmental niches and unconfirmed environmental sources, further support the spread and persistence of fungal pathogens. These drivers contribute to the emergence of pathogens like Candida auris, Candida orthopsilosis and Cryptococcus deuterogatii. Climate change and antifungal resistance: key mechanisms and pathogen examples. Climate change drives the development of antifungal resistance through mechanisms such as environmental pollution with fungicides, prolonged heat stress and increased mutation rates in fungi. These conditions promote genetic mutations, increased resistance to antifungal drugs and more challenging infections in humans and plants
1 17 30
Reposted by Martin Hoenigl
germhuntermd.bsky.social
Ilan Schwartz @germhuntermd.bsky.social · Jun 2
Diagnosis and Management of Candida Endophthalmitis and Chorioretinitis

Nate Permpalung, Sarah Sedik, Pete Pappas, @martinhoenigl.bsky.social, @drluiso.bsky.social in @cmijournal.bsky.social

www.clinicalmicrobiologyandinfection.com/article/S119...
Diagnosis and Management of Candida Endophthalmitis and Chorioretinitis
Candida endophthalmitis and chorioretinitis are uncommon but potentially devastating complications of candidemia, associated with significant risks of vision loss and long-term morbidity. Effective ma...
www.clinicalmicrobiologyandinfection.com
1 6 9
Reposted by Martin Hoenigl
ecmmcandidaiv.bsky.social
ecmmcandidaiv.bsky.social @ecmmcandidaiv.bsky.social · May 23
Proud to present the progress of ECMM Candida IV study at #ISHAM2025

Still open for participation!

@martinhoenigl.bsky.social
2 4
Reposted by Martin Hoenigl
olivercornely.bsky.social
Oliver Cornely @olivercornely.bsky.social · May 22
Yesterday at ISHAM 2025, Danila Seidel explored how environmental extremes can spark fungal outbreaks 🌪️🌱
A powerful reminder of climate’s role in emerging mycoses. #ISHAM2025 #FungalOutbreaks #ClimateAndHealth #MedicalMycology
1 9 20
Reposted by Martin Hoenigl
drneilstone.bsky.social
Dr Neil Stone @drneilstone.bsky.social · May 22
Did you know..75% of wine has significant levels of azole antifungals in it? (German wine anyway)

Potential consequences for driving resistance...

#IDSky #ISHAM
5 11 41
Reposted by Martin Hoenigl
drarghadip.bsky.social
Arghadip Samaddar, MD @drarghadip.bsky.social · May 22
Happy to meet some wonderful colleagues & brilliant minds in Medical Mycology.
@martinhoenigl.bsky.social @germhuntermd.bsky.social at #ISHAM2025 It has been an amazing congress with enriching academic sessions, lovely food & great hospitality at such a captivating location @fozdoiguacu.bsky.social
2 1 4
Reposted by Martin Hoenigl
olivercornely.bsky.social
Oliver Cornely @olivercornely.bsky.social · May 9
Thrilled to see Dr. Jon Salmanton-García receive the GEMICOMED Young Researcher Award 2025! His impactful research on invasive fungal & viral infections in hematologic malignancies is shaping the future of mycology: www.journalofinfection.com/article/S016... #FungalResearch #Mycology
1 4 8
martinhoenigl.bsky.social
Martin Hoenigl @martinhoenigl.bsky.social · Apr 29
Its fake news
4
Reposted by Martin Hoenigl
ecmmcandidaiv.bsky.social
ecmmcandidaiv.bsky.social @ecmmcandidaiv.bsky.social · Apr 24
Exciting news! The ECMM Candida IV study is now featured on the ECMM website! Find all the details here: www.ecmm.info/working-grou...

@martinhoenigl.bsky.social
Antifungal tolerance, resistance and clinical outcomes on candidemia caused by non-albicans Candida  - ECMM
ECMM Candida IV Antifungal tolerance, resistance and clinical outcomes on candidemia caused by non-albicans Candida  Observation periods/Timeline Observation period: April 1st, 2024 – September 30th, ...
www.ecmm.info
3 5
martinhoenigl.bsky.social
Martin Hoenigl @martinhoenigl.bsky.social · Apr 20
Sampling different types of grains at local markets in Namibia
starting our project

Fungal diversity of processed staple cereals from rural subsistence farming communities in Namibia

🙏🏻🙏🏻to colleagues from University of Namibia for hosting me
5
Reposted by Martin Hoenigl
olivercornely.bsky.social
Oliver Cornely @olivercornely.bsky.social · Apr 13
Honored to present today at ESCMID Global in Vienna: Ibrexafungerp salvage results from 233 patients in the FURI study — showing high success rates! 🔬💪 A promising new tool in the antifungal pipeline. #ESCMID2025 #FURIstudy #Ibrexafungerp #Antifungals #InfectiousDiseases
5 24
Reposted by Martin Hoenigl
ecmmcandidaiv.bsky.social
ecmmcandidaiv.bsky.social @ecmmcandidaiv.bsky.social · Apr 8
ECMM Candida IV Study is still open for participation

Global study on non-albicans candidemia

Requirements:

🔬Clinical data + isolates (no limit per site)
📅Apr 2024-Sep 2025
📦Ship isolates in one batch at study end
💰Case-based reimbursement available

@martinhoenigl.bsky.social
6 7
martinhoenigl.bsky.social
Martin Hoenigl @martinhoenigl.bsky.social · Apr 2
👉Participate in the ECMM Candida IV Study

🌍wide study on candidemia caused by non-albicans Candida

Requirement: clinical data & isolate (not req for C.auris)
Observation period: 04/2024 - 09/2025 Interested?

Email [email protected]
3 3
Reposted by Martin Hoenigl
galactic-europe.bsky.social
GALActIC @galactic-europe.bsky.social · Apr 2
On April 1, 2025, our project officially started. A significant milestone that we have worked towards for a long time. Now, we look forward to taking the next steps together.

@martinhoenigl.bsky.social
@simonfeys.bsky.social
@agocarvalho.bsky.social
1 2 5
martinhoenigl.bsky.social
Martin Hoenigl @martinhoenigl.bsky.social · Apr 2
Projekt „GALActIC“ startet: Biomarker für Pilzinfektionen erforscht

www.medunigraz.at/news/detail/...
Projekt „GALActIC“ startet: Biomarker für Pilzinfektionen erforscht
Eine internationale Studie unter Beteiligung der Med Uni Graz erforscht bestimmte Biomarker im Zusammenhang mit Pilzinfektionen.
www.medunigraz.at
1 2
Reposted by Martin Hoenigl
icvs-uminho.bsky.social
ICVS - Life and Health Sciences Research Institute | UMinho @icvs-uminho.bsky.social · Mar 31
🔬💡 ICVS Researchers Join Innovative GALActIC Study to Combat IAPA!
Researchers of the I3D team are part of this European project, aiming to improve the identification and treatment of Influenza-associated Pulmonary Aspergillosis and enhance patient care! 🙌
More at: icvs.uminho.pt/icvs-researc...
3 9
Reposted by Martin Hoenigl
donvinh.bsky.social
Don Vinh @donvinh.bsky.social · Mar 20
A potentially new antifungal class:
Mandimycin, polyene-like but targeting phospholipids, rather than ergosterol.
✅activity against yeasts in vivo 🐁
With insights from @olivercornely.bsky.social
@martinhoenigl.bsky.social
& David Denning

www.science.org/content/arti...
Deadly fungi are becoming drug-resistant. A new compound could beat them
A drug candidate with a new mechanism of action shows promise against several drug-resistant infections in mice
www.science.org
12 37
martinhoenigl.bsky.social
Martin Hoenigl @martinhoenigl.bsky.social · Mar 19
Deadly fungi are becoming drug-resistant. A new compound could beat them | Science | AAAS @kakape.bsky.social www.science.org/content/arti...
Deadly fungi are becoming drug-resistant. A new compound could beat them
A drug candidate with a new mechanism of action shows promise against several drug-resistant infections in mice
www.science.org
2 4
Reposted by Martin Hoenigl
olivercornely.bsky.social
Oliver Cornely @olivercornely.bsky.social · Mar 18
🔬 New research highlights a potential game-changer in treating invasive mould infections! 🦠 Patients show increased PD-1 expression, suggesting immune checkpoint inhibitors could help fight these deadly infections. More studies needed! 💡 onlinelibrary.wiley.com/doi/10.1111/... #Immunotherapy
Immune Phenotypes in Patients With Invasive Mould Infection Support the Use of PD‐1 Inhibition as Potential Treatment Option
Background Invasive mould infections (IMI) cause substantial morbidity and mortality in populations at risk. Novel treatment approaches are urgently needed. Targeting immune checkpoints may reverse ...
onlinelibrary.wiley.com
4 7
Reposted by Martin Hoenigl
galactic-europe.bsky.social
GALActIC @galactic-europe.bsky.social · Mar 17
New Medical Study Starting Soon 🔬

The logo was designed in collaboration with Galactic Partners, with professional support from Esra Sedik.

Follow us for more!

@martinhoenigl.bsky.social @agocarvalho.bsky.social
@simonfeys.bsky.social
1 4 6
Reposted by Martin Hoenigl
germhuntermd.bsky.social
Ilan Schwartz @germhuntermd.bsky.social · Mar 11
Are contemporary antifungal doses sufficient for critically ill patients? Outcomes from an international, multicenter PK study for Screening Antifungal Exposure in Intensive Care Units (SAFE-ICU)

J Roberts etc

TLDR: ++variable, need tailored approach w TDM

link.springer.com/article/10.1...
AUC0-24/MIC for two different durations of antifungal treatment in ICU: 1-3 days vs 4-7 days, shown for various antifungals (and for caspofungin and anidulafungin shown separately for C albicans and C glabrata) PK/PD target-related exposures per occasion of the study antifungals prescribed for treatment. The shaded area represents the PK/PD target used in this study. For fluconazole, 15 data points are outside the y-axis limits (max AUC0-24/MIC value was 3250.3); ICU intensive care unit; AUC0-24 area under the plasma concentration-time curve from zero to 24 h; fAUC0-24 free AUC0-24; MIC minimum inhibitory concentration; Cmin minimum observed plasma concentration; Cmax maximum observed plasma concentration
4 18